

WEST

Generate Collection

Print

L31: Entry 75 of 91

File: DWPI

Oct 31, 2002

DERWENT-ACC-NO: 2003-030109

DERWENT-WEEK: 200302

COPYRIGHT 2003 DERWENT INFORMATION LTD

TITLE: Increasing intraocular amount of biological agent, comprises providing to eye, a biological agent combined with a prostanoid, to increase the intraocular amount of the biological agent

INVENTOR: BERNAL, V; GLICKMAN, R D ; GRAYBILL, J R ; PARIS, G ; SPONSEL, W E

PRIORITY-DATA: 2001US-285856P (April 23, 2001)

PATENT-FAMILY:

PUB-NO	PUB-DATE	LANGUAGE	PAGES	MAIN-IPC
WO 200285248 A2	October 31, 2002	E	118	A61F000/00

INT-CL (IPC): A61 F 0/00

ABSTRACTED-PUB-NO: WO 200285248A

BASIC-ABSTRACT:

NOVELTY - Increasing intraocular amount of a biological agent, comprises providing to an eye at least a first biological agent combined with at least a first prostanoid, to increase the intraocular amount of the biological agent.

DETAILED DESCRIPTION - INDEPENDENT CLAIMS are also included for:

(1) an ophthalmically acceptable formulation comprising an ocular transport effective amount of at least a prostanoid and at least a biological agent; and

(2) kit comprising at least a container and a combination comprising at least a prostanoid and a biological agent.

ACTIVITY - Ophthalmological.

MECHANISM OF ACTION - Synergist.

No suitable biological data given.

USE - For increasing intraocular amount of a biological agent (such as where the intraocular amount increased is in the aqueous or vitreous of the eye), where the patient is suspected of having an acute or chronic infection, (such as preseptal, orbital or periorbital cellulitis, a microbial, bacterial, viral, retroviral, parasitic, fungal or amoebal infection), or HIV-, CMV- or HSV-associated retinal disorder, or gram positive or negative bacterial infection, staphylococcal infection, a Pseudomonas aeruginosa infection, candidiasis or aspergillosis, bacterial or fungal keratitis or endophthalmitis, uveitis, conjunctivitis, intraocular or periocular inflammation, an allergy or allergies affecting the eye, diabetes, glaucoma, ocular neovascular disease, retinal or macular degeneration, vitamin deficiency, optic neuropathy, a blunt or penetrating ocular injury or an orbital or intraocular tumor. For use where the patient is preparing to undergo eye surgery (e.g. cataract surgery), where the combination comprises a prostanoid and a surgically beneficial agent (e.g. anesthetic), or where the patient has been subjected to eye surgery and the combination comprises a prostanoid and a postoperative beneficial agent (e.g. anti-microbial, anti-bacterial, anti-viral, anti-retroviral, anti-parasitic or anti-fungal agent), (all claimed).

ADVANTAGE - The use of prostanoids effectively increases the transport and/or penetration of therapeutic agents into the eye.

BEST AVAILABLE COPY

WEST



Generate Collection

Print

L31: Entry 84 of 91

File: DWPI

Feb 9, 1984

DERWENT-ACC-NO: 1984-071333

DERWENT-WEEK: 198412

COPYRIGHT 2003 DERWENT INFORMATION LTD

TITLE: Anti-neoplastic complex prepn. from active agent and unsatd. fatty aci - to give less toxic, more specific prod.

PRIORITY-DATA: 1982JP-0133958 (July 31, 1982)

PATENT-FAMILY:

PUB-NO	PUB-DATE	LANGUAGE	PAGES	MAIN-IPC
JP 59025327 A	February 9, 1984		004	
JP 92049524 B	August 11, 1992		005	A61K031/71

INT-CL (IPC): A61K 31/20; A61K 31/71; C07H 15/252

ABSTRACTED-PUB-NO: JP 59025327A

BASIC-ABSTRACT:

Prepn. of an antineoplastic complex (I) is by reacting antineoplastics (II) with 10-30C unsatd. fatty acids. (II) are e.g. aminoglycoside antibiotics including daunorubicin, doxorubicin and adriamycin. Arachidonic acid and docosaehexaenoic acid are the most suitable fatty acids. (I) is much less toxic, and is more effective against target cancer cells. In an example, 24.1 mg. of water-soluble carbodiimide were added to 10.3 mg. of arachidonic acid, the mixt. was dissolved in 3 ml. of DMF and 10.0 mg. of daunorubicin in 2 ml. of distilled water were added dropwise with stirring. The mixture was stirred for about 6 hrs., then adjusted to alkaline pH with 4N NaOH. The complex was extracted with 3 x 40 ml. of chloroform and the extract was washed with distilled water, dried (Na₂SO₄) evaporated to dryness, then chromatographed on silica gel, and eluted with chloroform-acetone (7:3). The binding ratio of arachidonic acid to daunorubicin was 1:1.

Effect of this and other complexes on inoculated ascites hepatoma AH66 cells in rats was examined. In control rats, average duration of survival was 15 days. Average duration of survival in rats given daunorubicin or doxorubicin was 28 and 30 days, resp. In groups given various complexes, average duration of survival was more than 60 days.

BEST AVAILABLE COPY

WEST Search History

DATE: Monday, November 10, 2003

<u>Set Name</u>	<u>Query</u>	<u>Hit Count</u>	<u>Set Name</u>
side by side			result set
<i>DB=USPT,PGPB,JPAB,EPAB,DWPI; PLUR=YES; OP=ADJ</i>			
L10	L9 and l1	4	L10
L9	alpha-2-adrenergic agonist	58	L9
L8	drug or pharmaceutical or medicine	551570	L8
L7	nmda! or n-methyl-d-aspartate antagonist	4242	L7
L6	l1 and l5	13	L6
L5	\$35quinoxaline	9665	L5
L4	quinoxaline	7607	L4
L3	docosahexanoic acid	294	L3
L2	linolenic acid	10946	L2
L1	prostanoid	1486	L1

END OF SEARCH HISTORY